Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenaya Therapeutics Inc

1.10
-0.0350-3.10%
Volume:2.34M
Turnover:2.55M
Market Cap:178.46M
PE:-1.22
High:1.13
Open:1.12
Low:1.05
Close:1.13
52wk High:4.01
52wk Low:0.3600
Shares:162.98M
Float Shares:152.50M
Volume Ratio:0.36
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8943
EPS(LYR):-1.3101
ROE:-85.21%
ROA:-45.11%
PB:1.79
PE(LYR):-0.84

Loading ...

Tomohiro Higa, SVP of Finance, Reports Disposal of Tenaya Therapeutics Common Shares

Reuters
·
Aug 19

Ali Faraz, CEO, Reports Disposal of Common Shares of Tenaya Therapeutics Inc

Reuters
·
Aug 19

Buy Rating for Tenaya Therapeutics: Financial Stability and Promising Clinical Trial Results

TIPRANKS
·
Aug 11

Tenaya Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Reuters
·
Aug 08

Promising Pipeline and Financial Prudence Drive Buy Rating for Tenaya Therapeutics

TIPRANKS
·
Aug 08

Tenaya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 07

Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)

TIPRANKS
·
Aug 07

Tenaya Therapeutics Q2 net loss of $23.3 narrows

Reuters
·
Aug 07

Tenaya Therapeutics Q2 Basic EPS USD -0.14

THOMSON REUTERS
·
Aug 07

Tenaya Therapeutics Q2 Operating Expenses USD 24.082 Million

THOMSON REUTERS
·
Aug 07

Analysts Are Bullish on Top Healthcare Stocks: Tenaya Therapeutics (TNYA), ImmunoPrecise Antibodies (IPA)

TIPRANKS
·
Jul 31

Tenaya Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
Jul 31

Promising Developments in Tenaya Therapeutics’ Clinical Trials Earn Buy Rating from Analyst

TIPRANKS
·
Jul 30

Positive Safety Reviews and Promising Interim Data Bolster Buy Rating for Tenaya Therapeutics

TIPRANKS
·
Jul 30

Tenaya Therapeutics Inc: Plans to Report Longer-Term Follow-up Data From Cohort 1 and Initial Data From Cohort 2 in Q4 of This Year

THOMSON REUTERS
·
Jul 30

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

GlobeNewswire
·
Jul 30

Tenaya Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
May 31

Tenaya Therapeutics' SVP Finance Tomohiro Higa Reports Disposal of Common Shares

Reuters
·
May 17

Tingley Whittemore, Chief Medical Officer, Reports Disposal of Tenaya Therapeutics Inc. Common Shares

Reuters
·
May 17

CEO Ali Faraz Reports Disposal of Tenaya Therapeutics Inc. Common Shares

Reuters
·
May 17